PharVision Advisers
CLF icon

PharVision Advisers’s Cleveland-Cliffs CLF Stock Holding History

PharVision Advisers’s Portfolio CLF Stock Details CLF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-13,160
Closed -$124K – 38
2026
Q2 		$124K Buy
13,160
+2,387
+22% +$26.2K 2.33% 5
2026
Q1 		$91K Sell
10,773
-4,454
-29% -$51K 0.92% 57
2025
Q4 		$202K Buy
+15,227
New +$192K 0.1% 550

Other funds holding CLF

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

PharVision Advisers's CLF Position: Q3 2026 in Review

PharVision Advisers sold out of Cleveland-Cliffs (CLF) in Q3 2026, closing a stake of 13,160 shares — an estimated $124K sold.

PharVision Advisers first reported a position in CLF in Q4 2025 and held it in 3 quarters. The position peaked at $202K in Q4 2025. 274 funds tracked by Wall St. Rank hold CLF as of Q3 2026.

  • PharVision Advisers reported no remaining Cleveland-Cliffs position as of Q3 2026 after selling out during the quarter.
  • PharVision Advisers sold 13,160 Cleveland-Cliffs shares in Q3 2026, an estimated $124K.
  • PharVision Advisers first reported a position in Cleveland-Cliffs in Q4 2025 and held it in 3 quarters.
  • PharVision Advisers's Cleveland-Cliffs position peaked at $202K in Q4 2025.
  • 274 funds tracked by Wall St. Rank held Cleveland-Cliffs as of Q3 2026.

Based on PharVision Advisers's 13F filing for Q3 2026, filed 29 Oct 2026.